Health and Fitness Health and Fitness
Fri, August 17, 2012
Thu, August 16, 2012
Wed, August 15, 2012
Tue, August 14, 2012
Mon, August 13, 2012
Fri, August 10, 2012
Thu, August 9, 2012
Wed, August 8, 2012
Tue, August 7, 2012
Mon, August 6, 2012
Fri, August 3, 2012
Thu, August 2, 2012
[ Thu, Aug 02nd 2012 ] - Market Wire
00 p.m. EDT
Wed, August 1, 2012
[ Wed, Aug 01st 2012 ] - Market Wire
Head of European Operations
Tue, July 31, 2012
Mon, July 30, 2012
Sun, July 29, 2012
Fri, July 27, 2012
Thu, July 26, 2012
Wed, July 25, 2012
Tue, July 24, 2012
Mon, July 23, 2012

Medivation and Astellas Announce PDUFA Action Date for Enzalutamide NDA


//health-fitness.news-articles.net/content/2012/ .. unce-pdufa-action-date-for-enzalutamide-nda.html
Published in Health and Fitness on Friday, August 3rd 2012 at 14:32 GMT by Market Wire   Print publication without navigation


August 03, 2012 17:16 ET

Medivation and Astellas Announce PDUFA Action Date for Enzalutamide NDA

SAN FRANCISCO, CA and TOKYO--(Marketwire - Aug 3, 2012) -  Medivation, Inc. (NASDAQ: [ MDVN ]) and Astellas Pharma Inc. (TSE: 4503) today announced that the U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) action date of November 22, 2012 for the review of the investigational agent enzalutamide (formerly MDV3100) New Drug Application (NDA) for the potential treatment of men with castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy. The companies announced on July 24, 2012 that the FDA accepted the enzalutamide NDA filing for review and granted Priority Review Designation.

About Enzalutamide
Enzalutamide is an oral, once-daily investigational agent that is an androgen receptor signaling inhibitor. Enzalutamide inhibits androgen receptor signaling in three distinct ways: it inhibits 1) testosterone binding to androgen receptors; 2) nuclear translocation of androgen receptors; and 3) DNA binding and activation by androgen receptors.

In the Phase 3 AFFIRM trial common side effects observed more frequently in enzalutamide as compared with placebo-treated patients included fatigue, diarrhea and hot flush. Seizure was reported in less than 1% of enzalutamide-treated patients. Serious adverse events, adverse events causing patients to stop treatment, and adverse events causing death all were lower in the enzalutamide group than in the placebo group.

About Medivation
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel therapies to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their families. For more information, please visit us at [ www.medivation.com ].

About Astellas Pharma Inc.
Astellas Pharma Inc. is a pharmaceutical company dedicated to improving the health of people around the world through provision of innovative and reliable pharmaceuticals. The organization is committed to becoming a global category leader in oncology, and has several oncology compounds in development in addition to enzalutamide. For more information on Astellas Pharma Inc., please visit our website at [ www.astellas.com/en ].



Publication Contributing Sources